{"prompt": "['MC1575', '7', 'Amendment 2', 'reported a median duration of response of 20 months, and a median overall', 'survival of 3.3 years, broken down to 3.8 years for responders and 1.8 years for', 'non-responders, a difference however which is not statistically significant likely', 'due to the small number of patients (Huang, Abraham et al. 2008). Another', 'single institution cohort with different chemotherapy regimens also showed', 'similar results where median overall survival for responders was 6.4 years versus', '3.7 years for nonresponders (Ayala-Ramirez, Feng et al. 2012). While treatment', 'with CVD is generally well tolerated and can be administered for long periods of', 'time, (Averbuch, Steakley et al. 1988; Huang, Abraham et al. 2008; Ayala-', 'Ramirez, Feng et al. 2012) better systemic therapies are clearly needed, since the', 'majority of patients ultimately succumb to their disease despite therapy.', 'There is relatively little experience with other chemotherapeutic regiments,', 'generally limited to case reports or small series and include the combination', 'cisplatin and 5-FU (Srimuninnimit and Wampler 1991), lomustine and 5-FU or', 'capecitabine (Chrisoulidou, Kaltsas et al. 2007), carboplatin (Cairnduff and', 'Smith 1986), etoposide and cisplatin (Mertens, Grignon et al. 1993;', 'Chrisoulidou, Kaltsas et al. 2007), etoposide, carboplatin, vincristine,', 'cyclophosphamide and doxorubicin (Jirari, Charpentier et al. 1999),', 'modifications of CVD with doxorubicin (Patel, Winchester et al. 1995; Nakane,', 'Takahashi et al. 2003; Ayala-Ramirez, Feng et al. 2012), MAID (Fitoussi,', 'Debled et al. 1999), gemcitabine (Pipas and Krywicki 2000), paclitaxel', '(Kruijtzer, Beijnen et al. 2000), and temozolomide and thalidomide (Kulke,', 'Stuart et al. 2006). At least 2 case series have reported very poor results with', 'various chemotherapeutic regiments including cisplatin, etoposide, doxorubicin,', 'cyclophosphamide and dacarbazine (Massey and Wallner 1992; Schlumberger,', 'Gicquel et al. 1992). Recently, temozolomide (an oral prodrug of dacarbazine, an', 'agent used in the CVD regimen above) was reported to have 33% partial', 'response rate in a single center case series (Hadoux, Favier et al. 2014). Some', 'targeted therapies have also been tried with imatinib mesylate being ineffective', 'in 2 patients (Gross, Munter et al. 2006) and everolimus (RAD001) being also', 'ineffective (Chrisoulidou, Kaltsas et al. 2007; Oh, Kim et al. 2012).', '1.15', 'Pathophysiology and molecular characteristics of pheochromocytomas and', 'paragangliomas', 'Pheochromocytomas and paragangliomas are highly hypervascular tumors as', 'suggested by immunohistochemical studies of vascular density (Liu, Djuricin et', 'al. 1996; Ohji, Sasagawa et al. 2001). Quantitative as well as architectural', 'differences between benign and malignant tumors have been demonstrated (Liu,', 'Djuricin et al. 1996; Favier, Plouin et al. 2002; Zielke, Middeke et al. 2002). In', 'addition, several angiogenic growth factors and their receptors are overexpressed', 'in malignant pheochromocytomas and paragangliomas (Zielke, Middeke et al.', '2002; Salmenkivi, Heikkila et al. 2003; Favier, Igaz et al. 2012). From these,', 'vascular endothelium growth factor (VEGF), the most potent factor of vascular', 'development, is the most studied, and consistent overexpression at both the', 'genetic and protein expression level has been demonstrated (Favier, Plouin et al.', '2002; Zielke, Middeke et al. 2002; Salmenkivi, Heikkila et al. 2003). Several', 'other key angiogenic factors are also overexpressed such as the hypoxia induced', 'transcription factor EPAS1, and the endothelin receptors type A (ETA) and type', 'B (ETB) (Favier, Plouin et al. 2002). Anti-VEGF antibodies have been shown to', 'Protocol Version Date:16Aug2018']['MC1575', '8', 'Amendment 2', 'inhibit angiogenesis in experimental pheochromocytomas (Zielke, Middeke et al.', '2002).', 'The genetics of pheochromocytomas and paragangliomas are very complex', '(Dahia 2006). Adrenal pheochromocytoma is strongly associated with multiple', 'endocrine neoplasia 2A and 2B, von Hippel-Lindau disease (VHL), and familial', 'paraganglioma syndrome (Neumann, Bausch et al. 2002; Boedeker, Ridder et al.', '2005), and is less commonly seen with neurofibromatosis type 1 (NF 1) or MEN', '1. However, malignant adrenal pheochromocytoma is only infrequently seen in', 'association with these genetic syndromes. On the contrary, extra-adrenal', 'malignant paragangliomas are most frequently seen in association with familial', 'paraganglioma syndrome (PGL), an autosomal dominant disorder presenting', 'with paragangliomas in the head and neck, but also in the thorax, abdomen, and', 'urinary bladder (Neumann, Bausch et al. 2002; Boedeker, Ridder et al. 2005).', 'Most cases are caused by mutations in the succinate dehydrogenase gene (SDH)', 'subunits B, C and D even in apparent \"sporadic\" cases. Extra-adrenal malignant', 'paraganglioma is strongly associated with mutations of the B subunit of the gene', '(SDHB) (Amar, Baudin et al. 2007).', 'Global gene expression profiles of large series of sporadic pheochromocytomas', 'and paragangliomas have generated 2 unique transcription signatures', '(Eisenhofer, Bornstein et al. 2004; Dahia, Ross et al. 2005). In the first cluster are', 'mutations of the VHL, SDHB and SDHD genes known to be associated to VHL', 'and PGL syndromes; in the second cluster are mutations in the RET and NF1', 'genes associated with the MEN syndromes. Both VHL and SDH mutations are', 'known to dysregulate the hypoxia response (Dahia, Ross et al. 2005). VHL', 'mutations lead to hypoxia inducible factor (HIF) mediated hypoxia response with', 'activation of genes involved in angiogenesis, proliferation, cell survival and', 'death (Semenza 2002; Semenza 2002). Mutations in the SDH gene, an intergral', 'enzyme of the Krebs cycle, also lead to activation of HIF mediated hypoxia', 'signals likely through accumulation of Krebs cycle intermediates, mitochondrial', 'complex II inhibition, and HIF1a over-expression (Gimenez-Roqueplo Favier et', 'al. 2001; Gimenez-Roqueplo, Favier et al. 2002; Gottlieb and Tomlinson 2005;', 'Pollard, Briere et al. 2005; Selak, Armour et al. 2005; Dahia 2006).', '1.2', 'Kinase inhibitors as therapeutics in pheochromocytoma and paraganglioma', '1.21', 'Sunitinib', 'Sunitinib is an oral multikinase inhibitor of VEGFR1-3, platelet-derived growth', 'factor receptor (PDGFR)-o and -\u00df, stem cell factor receptor (c-Kit), FLT3, and', 'RET. Case studies and a case series from MD Anderson suggested benefit from', 'this agent in patients with advanced metastatic pheochromocytomas and', 'paragangliomas (Jimenez, Cabanillas et al. 2009; Joshua, Ezzat et al. 2009;', 'Ayala-Ramirez, Chougnet et al. 2012; Jimenez, Rohren et al. 2013).', '1.22', 'Pazopanib', 'A phase II trial was conducted at our institution (Bible, PI) to evaluate the effects', 'of another oral multikinase inhibitor, pazopanib, in patients with metastatic', 'pheochromocytomas and paragangliomas, initiated after observing promising', 'results in patients with metastatic differentiated thyroid cancers including', 'Protocol Version Date:16Aug2018']\n\n###\n\n", "completion": "END"}